Roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein cdk5. (Q40212826)

18 September 2017

Roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein cdk5. (English)

1 reference

18 September 2017

Shaun Goodyear

1

1 reference

PubMed ID

17081516

18 September 2017

Mahesh C Sharma

series ordinal

2

1 reference

PubMed ID

17081516

18 September 2017

language of work or name

1 reference

1 November 2006

1 reference

Experimental and Molecular Pathology

18 September 2017

1 reference

18 September 2017

82

1 reference

18 September 2017

1

1 reference

18 September 2017

25-32

1 reference

Cyclin D1 is a nuclear protein required for cell cycle progression in G1

18 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

Analysis of cell cycle-related gene expression in postmitotic neurons: selective induction of Cyclin D1 during programmed cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

CDK inhibition and cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

Cyclin dependent kinase regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

Chemical inhibitors of cyclin-dependent kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

Properties and potential-applications of chemical inhibitors of cyclin-dependent kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

Clinical highlights from the National Cancer Data Base: 1997.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

CDK-5-mediated neurofilament phosphorylation in SHSY5Y human neuroblastoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

Phosphorylation of MEK1 by cdk5/p35 down-regulates the mitogen-activated protein kinase pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

Angiostatin-induced inhibition of endothelial cell proliferation/apoptosis is associated with the down-regulation of cell cycle regulatory protein cdk5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

G1 phase progression: cycling on cue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

Inhibition of cyclin-dependent kinases by purine analogues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.09.002

10.1016/J.YEXMP.2006.09.002

7 January 2021

Identifiers

DOI

1 reference

18 September 2017

1 reference

PubMed ID

17081516